BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J Nucl Med 2018;59:1085-91. [DOI: 10.2967/jnumed.117.206631] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Eilsberger F, Kreissl MC, Luster M, Pfestroff A. [Therapy concepts for thyroid carcinoma]. Nuklearmedizin 2022;61:223-30. [PMID: 34644802 DOI: 10.1055/a-1650-9762] [Reference Citation Analysis]
2 Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Naik M, Al-Nahhas A, Khan SR. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now. Cancers (Basel) 2022;14:761. [PMID: 35159027 DOI: 10.3390/cancers14030761] [Reference Citation Analysis]
4 Metser U, Eshet Y, Ortega C, Veit-Haibach P, Liu A, K S Wong R. The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nucl Med Commun 2022;43:73-7. [PMID: 34887370 DOI: 10.1097/MNM.0000000000001488] [Reference Citation Analysis]
5 Pollard J, McNeely P, Menda Y. Nuclear Imaging of Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020;29:209-221. [PMID: 32151356 DOI: 10.1016/j.soc.2019.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Koshino K, Werner RA, Pomper MG, Bundschuh RA, Toriumi F, Higuchi T, Rowe SP. Narrative review of generative adversarial networks in medical and molecular imaging. Ann Transl Med 2021;9:821. [PMID: 34268434 DOI: 10.21037/atm-20-6325] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
8 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
9 Werner RA, Bengel FM, Derlin T. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Radiologe. 2020;60:413-420. [PMID: 32052116 DOI: 10.1007/s00117-020-00652-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Werner RA, Derlin T, Rowe SP, Bundschuh L, Sheikh GT, Pomper MG, Schulz S, Higuchi T, Buck AK, Bengel FM, Bundschuh RA, Lapa C. High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. J Nucl Med 2021;62:514-20. [PMID: 32859702 DOI: 10.2967/jnumed.120.245464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ambinder EB, Werner RA, Rowe SP. Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma. Radiol Case Rep 2020;15:1344-7. [PMID: 32617128 DOI: 10.1016/j.radcr.2020.05.054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Werner RA, Hänscheid H, Leal JP, Javadi MS, Higuchi T, Lodge MA, Buck AK, Pomper MG, Lapa C, Rowe SP. Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution. Mol Imaging Biol 2019;21:790-8. [PMID: 30406512 DOI: 10.1007/s11307-018-1293-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine 2020;67:9-19. [PMID: 31734779 DOI: 10.1007/s12020-019-02131-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Lapa C. Exciting Opportunities in Nuclear Medicine Imaging and Therapy. J Clin Med 2019;8:E1944. [PMID: 31718092 DOI: 10.3390/jcm8111944] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 2019;8:E1060. [PMID: 31331016 DOI: 10.3390/jcm8071060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
16 Paola M, Mansi L. Molecular Imaging and Theranostics in Pancreatic Neuroendocrine Tumours: From a Luminous Present to an Even Brighter Future. CRP 2019;12:93-5. [DOI: 10.2174/187447101202190530074002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Paola M, De Cobelli F, Picchio M. PET/MRI in Neuroendocrine Tumours: Blessings and Curses. CRP 2019;12:96-7. [DOI: 10.2174/1874471012999190404151701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine 2019;49:255-70. [DOI: 10.1053/j.semnuclmed.2019.02.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
19 Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med 2019;60:1266-9. [PMID: 30850506 DOI: 10.2967/jnumed.118.223016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
20 Werner RA, Bundschuh RA, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP. Novel Structured Reporting Systems for Theranostic Radiotracers. J Nucl Med 2019;60:577-84. [PMID: 30796171 DOI: 10.2967/jnumed.118.223537] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
21 Kazuhiro K, Werner RA, Toriumi F, Javadi MS, Pomper MG, Solnes LB, Verde F, Higuchi T, Rowe SP. Generative Adversarial Networks for the Creation of Realistic Artificial Brain Magnetic Resonance Images. Tomography 2018;4:159-63. [PMID: 30588501 DOI: 10.18383/j.tom.2018.00042] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
22 Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 2018;8:6088-100. [PMID: 30613284 DOI: 10.7150/thno.30357] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
23 Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging. J Nucl Med 2018;59:1857-64. [PMID: 30190304 DOI: 10.2967/jnumed.118.217588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
24 Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhbahaei S, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Ann Nucl Med 2018;32:512-22. [PMID: 30109562 DOI: 10.1007/s12149-018-1291-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]